Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTNM NASDAQ:INDP NASDAQ:MNPR NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$14.15-0.3%$12.99$3.72▼$16.33$530.51M0.89430,871 shs3.89 million shsINDPIndaptus Therapeutics$3.38-0.8%$2.63$0.92▼$13.40$382.98M1.252.96 million shs138,087 shsMNPRMonopar Therapeutics$87.68$62.26$29.18▼$105.00$587.46M1.52146,187 shs310,267 shsONCYOncolytics Biotech$0.95$0.92$0.71▼$1.51$113.12M1.071.58 million shs774,280 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics0.00%+18.51%+4.89%+13.56%+244.28%INDPIndaptus Therapeutics0.00%-13.28%+92.16%+90.00%-70.95%MNPRMonopar Therapeutics0.00%+29.50%+34.81%+64.53%+160.95%ONCYOncolytics Biotech0.00%-1.27%-8.87%+17.74%+26.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTNMContineum Therapeutics$14.15-0.3%$12.99$3.72▼$16.33$530.51M0.89430,871 shs3.89 million shsINDPIndaptus Therapeutics$3.38-0.8%$2.63$0.92▼$13.40$382.98M1.252.96 million shs138,087 shsMNPRMonopar Therapeutics$87.68$62.26$29.18▼$105.00$587.46M1.52146,187 shs310,267 shsONCYOncolytics Biotech$0.95$0.92$0.71▼$1.51$113.12M1.071.58 million shs774,280 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTNMContineum Therapeutics0.00%+18.51%+4.89%+13.56%+244.28%INDPIndaptus Therapeutics0.00%-13.28%+92.16%+90.00%-70.95%MNPRMonopar Therapeutics0.00%+29.50%+34.81%+64.53%+160.95%ONCYOncolytics Biotech0.00%-1.27%-8.87%+17.74%+26.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTNMContineum Therapeutics 2.40Hold$20.0041.34% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/AMNPRMonopar Therapeutics 3.00Buy$107.9123.07% UpsideONCYOncolytics Biotech 2.75Moderate Buy$8.50796.81% UpsideCurrent Analyst Ratings BreakdownLatest ONCY, MNPR, CTNM, and INDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$105.006/25/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/2/2026MNPRMonopar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/2/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/29/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ONCYOncolytics Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/14/2026CTNMContineum Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$14.00 ➝ $16.005/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTNMContineum TherapeuticsN/AN/AN/AN/A$6.99 per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTNMContineum Therapeutics-$59.98M-$1.95N/AN/AN/AN/A-27.09%-25.64%8/4/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)MNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)ONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-2,185.97%-321.54%7/31/2026 (Estimated)Latest ONCY, MNPR, CTNM, and INDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A5/5/2026Q1 2026CTNMContineum Therapeutics-$0.55-$0.39+$0.16-$0.39N/AN/A3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTNMContineum TherapeuticsN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTNMContineum TherapeuticsN/A38.0038.00INDPIndaptus TherapeuticsN/A2.342.34MNPRMonopar TherapeuticsN/A56.0456.04ONCYOncolytics BiotechN/A1.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTNMContineum TherapeuticsN/AINDPIndaptus Therapeutics7.06%MNPRMonopar Therapeutics1.83%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipCTNMContineum Therapeutics7.90%INDPIndaptus Therapeutics23.60%MNPRMonopar Therapeutics9.70%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTNMContineum Therapeutics3137.39 million34.43 millionN/AINDPIndaptus Therapeutics6113.24 million86.52 millionNot OptionableMNPRMonopar Therapeutics106.70 million6.05 millionNot OptionableONCYOncolytics Biotech30119.35 million119.24 millionNot OptionableONCY, MNPR, CTNM, and INDP HeadlinesRecent News About These CompaniesReviewing Oncolytics Biotech (NASDAQ:ONCY) & Scinai Immunotherapeutics (NASDAQ:SCNI)June 27 at 3:49 AM | americanbankingnews.comOncolytics Biotech Secures New Pelareorep Manufacturing PatentJune 16, 2026 | tipranks.comOncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044June 16, 2026 | globenewswire.comOncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor AttentionJune 5, 2026 | finance.yahoo.comOncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating OfficerJune 2, 2026 | globenewswire.comONCY stock heads for sixth straight session of gains – lead therapy shines in early combination treatment studyJune 1, 2026 | msn.comOncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted ApproachesJune 1, 2026 | globenewswire.comOncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal TumorsMay 22, 2026 | globenewswire.comONCY: Aligns with FDA on pivotal trial for Pelareorep in anal cancerMay 19, 2026 | msn.comOncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal CancerMay 4, 2026 | globenewswire.comOncolytics Biotech, Inc.: Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyApril 27, 2026 | finanznachrichten.deOncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyApril 27, 2026 | globenewswire.comOncolytics Could Re-Rate As Pelareorep Focuses On Registrational PathsApril 25, 2026 | seekingalpha.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Oncolytics Biotech (ONCY)April 12, 2026 | theglobeandmail.comOncolytics Plans FDA Meeting for Pelareorep SCAC StudyApril 7, 2026 | theglobeandmail.comONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of PelareorepApril 7, 2026 | msn.comOncolytics Biotech Establishes $75 Million ATM OfferingApril 6, 2026 | tipranks.comOncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal CancerApril 6, 2026 | globenewswire.comOncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade OffApril 1, 2026 | finance.yahoo.comOncolytics Biotech® Completes Domicile Change to the United StatesApril 1, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCY, MNPR, CTNM, and INDP Company DescriptionsContineum Therapeutics NASDAQ:CTNM$14.15 -0.04 (-0.28%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$14.19 +0.04 (+0.28%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.Indaptus Therapeutics NASDAQ:INDP$3.38 -0.03 (-0.82%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$3.42 +0.03 (+0.98%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Monopar Therapeutics NASDAQ:MNPR$87.68 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$86.54 -1.15 (-1.31%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Oncolytics Biotech NASDAQ:ONCY$0.95 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.94 -0.01 (-0.82%) As of 08:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback Winnebago Misses Estimates, But Surges 14% After Earnings 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
